Bibliotecas PUC-SP - Busca Integrada

CDK4/6 inhibition in breast cancer: current practice and future directions

por Sonia Pernas, Sara M. Tolaney, Eric P. Winer, Shom Goel
Publicado no Therapeutic Advances in Medical Oncology (2018-07-01)

Should a Sentinel Node Biopsy Be Performed in Patients with High-Risk Breast Cancer?

por Kenneth D. Westover, M. Brandon Westover, Eric P. Winer, Andrea L. Richardson, J. Dirk Iglehart, Rinaa S. Punglia
Publicado no International Journal of Breast Cancer (2011-01-01)

Survival Implications Associated with Variation in Mastectomy Rates for Early-Staged Breast Cancer

por John M. Brooks, Elizabeth A. Chrischilles, Mary Beth Landrum, Kara B. Wright, Gang Fang, Eric P. Winer, Nancy L. Keating
Publicado no International Journal of Surgical Oncology (2012-01-01)

Diet and physical activity interventions in Black and Latina women with breast cancer: A scoping review

por Margaret S. Pichardo, Margaret S. Pichardo, Tara Sanft, Tara Sanft, Leah M. Ferrucci, Leah M. Ferrucci, Yaideliz M. Romero-Ramos, Brenda Cartmel, Brenda Cartmel, Maura Harrigan, Ana I. Velazquez, Oluwadamilola M. Fayanju, Eric P. Winer, Eric P. Winer, Melinda L. Irwin, Melinda L. Irwin
Publicado no Frontiers in Oncology (2023-03-01)

Post-diagnosis weight trajectories and mortality among women with breast cancer

por Leah S. Puklin, Fangyong Li, Brenda Cartmel, Julian Zhao, Tara Sanft, Alexa Lisevick, Eric P. Winer, Maryam Lustberg, Donna Spiegelman, Mona Sharifi, Melinda L. Irwin, Leah M. Ferrucci
Publicado no npj Breast Cancer (2023-12-01)

p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases

por Jing Ni, Sheheryar Kabraji, Shaozhen Xie, Yanzhi Wang, Peichen Pan, Xiaofang He, Zongming Liu, Jose Palbo Leone, Henry W. Long, Myles A. Brown, Eric P. Winer, Deborah A. R. Dillon, Nancy U. Lin, Jean J. Zhao
Publicado no Nature Communications (2022-03-01)

Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors

por Tal Sella, Yue Zheng, Shoshana M. Rosenberg, Kathryn J. Ruddy, Shari I. Gelber, Rulla M. Tamimi, Jeffrey M. Peppercorn, Lidia Schapira, Virginia F. Borges, Steven E. Come, Lisa A. Carey, Eric P. Winer, Ann H. Partridge
Publicado no npj Breast Cancer (2023-04-01)

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)

por Tal Sella, Yue Zheng, Nabihah Tayob, Kathryn J. Ruddy, Rachel A. Freedman, Chau Dang, Denise Yardley, Steven J. Isakoff, Vicente Valero, Michelle DeMeo, Harold J. Burstein, Eric P. Winer, Antonio C. Wolff, Ian Krop, Ann H. Partridge, Sara M. Tolaney
Publicado no npj Breast Cancer (2022-11-01)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer

por Sara M Tolaney, Tianyu Li, Edward T Richardson, Judith Agudo, Elizabeth A Mittendorf, Beth Overmoyer, Eric P Winer, Adrienne G Waks, Tanya E Keenan, Nabihah Tayob, Gerburg M Wulf, Victoria Attaya, Leilani Anderson, Ian E Krop, Eliezer M Van Allen
Publicado no Journal for ImmunoTherapy of Cancer (2022-10-01)

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study

por Romualdo Barroso-Sousa, Tanya E. Keenan, Tianyu Li, Nabihah Tayob, Lorenzo Trippa, Ricardo G. Pastorello, Edward T. Richardson III, Deborah Dillon, Zohreh Amoozgar, Beth Overmoyer, Stuart J. Schnitt, Eric P. Winer, Elizabeth A. Mittendorf, Eliezer Van Allen, Dan G. Duda, Sara M. Tolaney
Publicado no npj Breast Cancer (2021-08-01)

Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy

por Javier Cortes, Oleg Lipatov, Seock-Ah Im, Anthony Goncalves, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Shoichiro Ohtani, Nadia Harbeck, Sherene Loi, Roberto Salgado, Vassiliki Karantza, Jaime Mejia, Razvan Cristescu, Andrey Loboda, Michael Nebozhyn, Petar Jelinic, Lingkang Huang, Eric P. Winer
Publicado no npj Breast Cancer (2025-10-01)

Helping ourselves, helping others: the Young Women’s Breast Cancer Study (YWS) – a multisite prospective cohort study to advance the understanding of breast cancer diagnosed in wom...

por Lidia Schapira, Yue Zheng, Laura Collins, Ann H Partridge, Jeffrey Peppercorn, Virginia F Borges, Rulla M Tamimi, Gregory J Kirkner, Eric P Winer, Kathryn Ruddy, Shoshana M Rosenberg, Philip D Poorvu, Craig Snow, Meghan E Meyer, Steven Come, Ellen Warner, Shari Gelber
Publicado no BMJ Open (2024-06-01)

Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases

por Jose Pablo Leone, Kyrre E. Emblem, Michelle Weitz, Rebecca S. Gelman, Bryan P. Schneider, Rachel A. Freedman, Jerry Younger, Marco C. Pinho, A. Gregory Sorensen, Elizabeth R. Gerstner, Gordon Harris, Ian E. Krop, Daniel Morganstern, Jessica Sohl, Jiani Hu, Elizabeth Kasparian, Eric P. Winer, Nancy U. Lin
Publicado no Breast Cancer Research (2020-11-01)

Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE‐119

por Javier Cortes, Eric P Winer, Oleg Lipatov, Seock‐Ah Im, Anthony Gonçalves, Eva Muñoz‐Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Stephanie Hund, Karina Kulangara, Vassiliki Karantza, Jaime A Mejia, Junshui Ma, Petar Jelinic, Lingkang Huang, Scott K Pruitt, Kenneth Emancipator
Publicado no The Journal of Pathology: Clinical Research (2024-05-01)

STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

por Qiwei Wang, Johann S. Bergholz, Liya Ding, Ziying Lin, Sheheryar K. Kabraji, Melissa E. Hughes, Xiadi He, Shaozhen Xie, Tao Jiang, Weihua Wang, Jason J. Zoeller, Hye-Jung Kim, Thomas M. Roberts, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Deborah A. Dillon, Eric P. Winer, Nancy U. Lin, Jean J. Zhao
Publicado no Nature Communications (2022-05-01)

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer

por Adrienne G. Waks, Neelam V. Desai, Tianyu Li, Philip D. Poorvu, Ann H. Partridge, Natalie Sinclair, Laura M. Spring, Meredith Faggen, Michael Constantine, Otto Metzger, Jillian Alberti, Julia Deane, Shoshana M. Rosenberg, Elizabeth Frank, Sara M. Tolaney, Ian E. Krop, Nadine M. Tung, Nabihah Tayob, Tari A. King, Elizabeth A. Mittendorf, Eric P. Winer
Publicado no npj Breast Cancer (2022-05-01)

Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

por Ana C. Garrido-Castro, Cristina Saura, Romualdo Barroso-Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo, Joaquin Gavilá, Violeta Serra, Aleix Prat, Laia Paré, Pamela Céliz, Patricia Villagrasa, Yisheng Li, Jennifer Savoie, Zhan Xu, Carlos L. Arteaga, Ian E. Krop, David B. Solit, Gordon B. Mills, Lewis C. Cantley, Eric P. Winer, Nancy U. Lin, Jordi Rodon
Publicado no Breast Cancer Research (2020-11-01)

The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer

por Michalina Janiszewska, Shayna Stein, Otto Metzger Filho, Jennifer Eng, Natalie L. Kingston, Nicholas W. Harper, Inga H. Rye, Maša Alečković, Anne Trinh, Katherine C. Murphy, Elisabetta Marangoni, Simona Cristea, Benjamin Oakes, Eric P. Winer, Ian E. Krop, Hege G. Russnes, Paul T. Spellman, Elmar Bucher, Zhi Hu, Koei Chin, Joe W. Gray, Franziska Michor, Kornelia Polyak
Publicado no JCI Insight (2021-06-01)

HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

por Zheqi Li, Otto Metzger Filho, Giuseppe Viale, Patrizia dell’Orto, Leila Russo, Marie-Anne Goyette, Avni Kamat, Denise A. Yardley, Vandana Gupta Abramson, Carlos L. Arteaga, Laura M. Spring, Kami Chiotti, Carol Halsey, Adrienne G. Waks, Tari A. King, Susan C. Lester, Jennifer R. Bellon, Eric P. Winer, Paul T. Spellman, Ian E. Krop, Kornelia Polyak
Publicado no The Journal of Clinical Investigation (2024-04-01)

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

por Mattia Rediti, Aranzazu Fernandez-Martinez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker, Baljit Singh, Jordan D. Campbell, Karla V. Ballman, David W. Hillman, Eric P. Winer, Sarra El-Abed, Martine Piccart, Serena Di Cosimo, William Fraser Symmans, Ian E. Krop, Roberto Salgado, Sherene Loi, Lajos Pusztai, Charles M. Perou, Lisa A. Carey, Christos Sotiriou
Publicado no Nature Communications (2023-11-01)